Rong Li

1 month ago | nature.com | Abdulrahman D. Ibrahim |Zihao Liang |Hafiza Kashaf Tariq |Rong Li |Xuechen Chen |Shu Xu | +6 more

Despite the success of cancer immunotherapy in treating hematologic malignancies, their efficacy in solid tumors remains limited due to the immunosuppressive tumor microenvironment (TME), which is mainly formed by myeloid-derived suppressor cells (MDSCs). MDSCs not only exert potent immunosuppressive effects that hinder the success of immune checkpoint inhibitors (ICIs) and adaptive cellular therapies, but they also promote tumor advancement through non-immunological pathways, including promoting angiogenesis, driving epithelial-mesenchymal transition (EMT), and contributing to the establishment of pre-metastatic environments. While targeting MDSCs alone or in combination with conventional therapies has shown limited success, emerging evidence suggests that MDSC checkpoint blockade in combination with other immunotherapies holds great promise in overcoming both immunological and non-immunological barriers. In this review, we discussed the dual roles of MDSCs, with a particular emphasis on their underexplored checkpoints blockade strategies. We discussed the rationale behind combination strategies, their potential advantages in overcoming MDSC-mediated immunosuppression, and the challenges associated with their development. Additionally, we highlight future research directions aimed at optimizing combination immunotherapies to enhance cancer therapeutic effectiveness, particularly in solid tumor therapies where MDSCs are highly prevalent.

Dec 20, 2024 | cell.com | Yang Chen |Hao Qin |Nan Li |Yaohua Wei |Yixuan Lin |Ronghui Deng | +10 more

Keywords autologous tumor vaccines tumor membrane antigens neoadjuvant chemotherapy liposomal doxorubicin Introduction Surgery continues to be the primary treatment modality for the majority of solid tumors; however, the challenges of postoperative tumor recurrence and metastasis persist.1,2 Various strategies have been devised in response to these challenges, including using autologous tumor vaccine.3,4,5 These personalized vaccines leverage patients’ tumor cells as a source of antigens to...

Nov 20, 2024 | cell.com | Marco Seehawer |Zheqi Li |Triet M. Bui |Pierre Foidart |Jun Nishida |Clive S. D’Santos | +18 more

ResultsBoth KDM5A and KDM5B were reported to be amplified and overexpressed in breast cancer.7,14 However, paralog-specific differences between luminal and basal breast cancer have not been analyzed. Thus, we assessed the mutational landscape of KDM5 paralogs in luminal A (LumA) and basal breast tumors in the TCGA cohort.

Nov 6, 2024 | dialnet.unirioja.es | Yan Luo |Huan Liu |Ye Chen |Rong Li

Ayuda Buscar en la ayuda Buscar en la ayuda Association between fibroblast growth factor-23 and vascular calcification in athletic patients: A meta-analysis Yan-Kun Luo [1] ; Huan Liu [2] ; Ye Chen [2] ; Rong-Shan Li [1] ; Yun Zhou [1] [1] Shanxi Provincial People’s Hospital [2] Shanxi Medical University Localización: Revista Internacional de Medicina y Ciencias de la Actividad Física y del Deporte, ISSN-e 1577-0354, Vol. 24, Nº. 95, 2024, págs. 524-537 Idioma: inglés Títulos paralelos:...

Oct 17, 2024 | mdpi.com | Scott Gibson |Yanan Liu |Rong Li |Brett Hurst

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.